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Diagnosis, Evaluation and Monitoring
of Asthma
Asthma is a common condition, and diagnosis, sever-
ity, and control of the disease can be determined both
subjectively and objectively. It is important to assume
that recurrent breathlessness is due to asthma in pri-
mary care. Treatment without a definite diagnosis
and a careful monitoring of the disease risks unneces-
sary side effects and costs, and may fail to identify
and address the real issue. Physical examination of
the patient is one of the initial steps to diagnose
asthma, where abnormal lung sounds including
wheezing and rhonchi are characteristic.
In this issue of Allergology International, Na-
gasaka1 describes that an increase of the frequency
andor intensity of lung sounds is associated with air-
way wall oscillation and vortex shedding in central
airways, and that this change may be more sensitive
to airway narrowing than the appearance of wheezing
and rhonchi.2 He also emphasizes the importance of a
forced expiratory wheeze, which is an early sign of
airway obstruction in patients with mild asthma, and
points out possible usefulness of a recently developed
computerized and automated analysis of lung sound
in the management of the disease.3
There is ample evidence that endogenous nitric ox-
ide (NO) plays a role in regulating airway function
and that upregulation of NO by inflammatory cytoki-
nes and mediators in the airways can be monitored
easily in exhaled air. Munakata4 implicates in this is-
sue that exhaled NO ( FeNO ) is a non-invasive
marker of airway inflammation. In asthma, increased
FeNO reflects eosinophil-mediated inflammatory
pathways moderately well and predicts good re-
sponses to treatment with inhaled corticosteroid.5
Therefore, FeNO may be a useful way to monitor
asthma and prevent asthma exacerbations. However,
recent randomized controlled trials have reported
only equivocal benefits of adding measurements of
FeNO to usual examinations such as spirometry.
More longitudinal studies are needed to further de-
termine the potential use of FeNO in various pheno-
types of asthma in relation to other biomarkers relat-
ing airway inflammation, bronchial hyperresponsive-
ness and airflow limitation.
The impulse oscillation system (IOS) has recently
been introduced into clinical practice. The IOS is a
type of forced oscillation technique (FOT), which can
evaluate respiratory resistance and reactance at vari-
ous oscillatory frequencies to determine properties
not measurable by spirometry or body plethysmogra-
phy.6 This method is non-invasive and can be applied
for children and elderly subjects with a low depend-
ency on cooperation during tidal breathing. Various
IOS measures correlate with predicted FEV1, RV
TLC, ΔN2 of a single nitrogen washout test, thereby
separately detecting large and small airways abnor-
malities. In this issue of Allergology International,
Mochizuki et al.7 and Tanaka et al.8 describe the role
of IOS as a biomarker of childhood asthma and adult
asthma, respectively, and the latter authors also dem-
onstrate the effect of transdermal long-acting β2 ago-
nist patch on IOS measures. Favorable sensitivity and
specificity of IOS #3) in addition to its broad applica-
tion to patients merits the consideration to incorpo-
rate IOS into future asthma guidelines, but further
studies are required to clarify clinical implication of
each IOS indices.
Other than the above 4 review series articles, we
have one more review article which is written by Hi-
gashi et al.9 who received the JSA Best Presentation
Award 2010. They discuss about the usefulness of uri-
nary biomarkers for aspirin-intolerant asthma, i. e. ,
leukotriene E4 and prostaglandin D2 metabolites.
As has recently been reported by many research-
ers using genome-wide analysis, IL-33 and its recep-
tor polymorphisms are most significantly related to
the onset of asthma. However, the mechanisms in-
volved in the expression of these molecules have re-
mained unrevealed yet. Among 10 original articles
and 5 letters to the editor, we would like to introduce
the article written by Baba et al..10 They found that a
transcription factor, PU.1 positively regulates the ex-
pression of IL-33 receptor, ST2 on mast cells and ba-
sophils. Development of a new drug down-regulating
IL-33 receptor is expected.
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